What type of study is this?

This is a Human Clinical Trial study (also classified as: RCT).

December 8, 2025BloodOpen Access

Umbilical cord blood microtransplantation as consolidation therapy for elderly patients with newly diagnosed Acute Myeloid Leukemia: A single-center randomized controlled trial

View Full Paper

Ask AI

Bookmark

Hematopoietic recovery reached 77.8% in the UCBM group compared to 33.3% in controls, highlighting significant benefits.
Median survival time was significantly longer at 25.27 months in the UCBM group versus 15.47 months in controls (p=0.019).
This randomized controlled trial examined the efficacy of umbilical cord blood microtransplantation in newly diagnosed elderly AML patients.
UCBM may enable safer treatment options for elderly AML without increasing graft-versus-host disease risk.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Randomized controlled trial demonstrates improved outcomes in elderly patients with AML, suggesting umbilical cord blood microtransplantation may enhance efficacy and safety.

Cite This Study

Zhang et al. (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d87e https://doi.org/10.1182/blood-2025-4189

View Full Paper

Ask AI

Bookmark

Implication

Randomized controlled trial demonstrates improved outcomes in elderly patients with AML, suggesting umbilical cord blood microtransplantation may enhance efficacy and safety.

Umbilical cord blood microtransplantation as consolidation therapy for elderly patients with newly diagnosed Acute Myeloid Leukemia: A single-center randomized controlled trial

Key Points

Discussion

Implication

Cite This Study

Umbilical cord blood microtransplantation as consolidation therapy for elderly patients with newly diagnosed Acute Myeloid Leukemia: A single-center randomized controlled trial

Key Points

Discussion

Implication

Cite This Study

Keep reading

Keep reading